FDA, Tirzepatide

The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.
FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
The FDA says the Zepbound shortage is over. That's rattling the weight loss industry
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli Lilly’s (LLY) popular diabetes and weight-loss drugs Mounjaro and Zepbound — is officially over.
FDA Approves Weight Loss Medication Zepbound to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat their obstructive sleep apnea.
US FDA approves use of weight loss drug for sleep apnoea: Here’s all you need to know
The drug has been approved for use in combination with a low-calorie diet and increased physical activity in those with moderate to severe OSA. This shows that the weight-loss drug has multifarious uses other than controlling type-2 diabetes and obesity.
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
FDA says tirzepatide shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
healthday37m
FDA Approves Generic GLP-1 Medicine For Diabetes Treatment
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
The Spokesman-Review18h
FDA approves weight-loss drug Zepbound to treat sleep apnea
The FDA first approved Zepbound to treat obesity in November 2023. Its active ingredient, tirzepatide, was previously ...
MedPage Today6d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
Everyday Health2d
FDA Says Shortages of GLP-1 Drugs Mounjaro and Zepbound Are Over
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...
McKnight's Long-Term Care News9h
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.